Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes.

ABSTRACT:

Objective

Ranolazine is an antianginal drug that mediates its effects by inhibition of cardiac late sodium current. Although ranolazine is not approved for the treatment of type 2 diabetes, in post hoc analyses of pivotal angina trials, ranolazine was associated with reductions in percent glycosylated hemoglobin (HbA1c) in subjects with type 2 diabetes. The study prospectively assessed the safety and efficacy of ranolazine in subjects with type 2 diabetes with inadequate glycemic control managed by lifestyle alone.

Research design and methods

The study was conducted worldwide in 465 subjects, with baseline HbA1c of 7-10% (53-86 mmol/mol) and fasting serum glucose of 130-240 mg/dL, randomized to placebo versus ranolazine.

Results

Compared with placebo, there was a grea

SUBMITTER: Eckel RH 

PROVIDER: S-EPMC4477340 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature